Skip to main navigation
Skip to search
Skip to main content
Northern Arizona University Home
Home
Profiles
Departments and Centers
Scholarly Works
Activities
Grants
Datasets
Prizes
Search by expertise, name or affiliation
Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
Michael T. Barrett
, Ray Deiotte
, Elizabeth Lenkiewicz
, Smriti Malasi
, Tara Holley
, Lisa Evers
, Richard G. Posner
, Timothy Jones
, Haiyong Han
, Mark Sausen
, Victor E. Velculescu
, Jeffrey Drebin
, Peter O'Dwyer
, Gayle Jameson
, Ramesh K. Ramanathan
, Daniel D. Von Hoff
Biological Sciences
Research output
:
Contribution to journal
›
Article
›
peer-review
33
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinical study of genomic drivers in pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cancer Genome
25%
CDKN2A Deletion
25%
Chemoradiation
25%
Clinical Trials
50%
Clinically Significant
50%
Complex Genomes
25%
Copy number Aberrations
25%
Copy number Analysis
25%
DNA Repair
25%
Enhancer Region
25%
Fibrotic Stroma
25%
Genetic Drivers
100%
Genome Copy number
25%
Homozygous Deletion
25%
Lethal Cancer
25%
Metastasis
25%
Metastatic Disease
25%
Nave
25%
Novel Treatments
25%
Overall Survival
25%
Pancreas
25%
Pancreatic Cancer
25%
Pancreatic Ductal Adenocarcinoma
100%
Patient Outcomes
25%
Primary Disease
25%
Progression-free Survival
25%
SMAD4
25%
Somatic Aberrations
25%
Standing up
25%
Super-enhancer
25%
Surgical Resection
25%
Targeted Sequencing
25%
Tumor
50%
Whole Exome Sequencing
25%
Whole Genome
25%
Medicine and Dentistry
Biopsy
25%
Chemoradiotherapy
25%
Clinical Study
100%
Clinical Trial
50%
DNA Repair
25%
Enhancer Region
25%
Exome Sequencing
25%
Malignant Neoplasm
50%
Metastatic Carcinoma
50%
Neoplasm
50%
Overall Survival
25%
Pancreas Adenocarcinoma
100%
Pancreas Cancer
25%
Progression Free Survival
25%
Somatics
25%
Stroma
25%
Surgery
25%
Biochemistry, Genetics and Molecular Biology
Clinical Study
100%
Clinical Trial
100%
DNA Repair
50%
Enhancer Region
50%
Exome Sequencing
50%
Overall Survival
50%
Progression Free Survival
50%